US equities
|
META
$623.41
▼-1.13%
TSLA
$407.81
▲+4.13%
MU
$931.94
▲+3.12%
NVDA
$217.48
▲+0.69%
SPCX
$149.59
▲+1.83%
AMD
$558.99
▲+5.22%
AAPL
$347.21
▲+0.96%
SNDK
$1,302.29
▲+3.72%
META
$623.41
▼-1.13%
TSLA
$407.81
▲+4.13%
MU
$931.94
▲+3.12%
NVDA
$217.48
▲+0.69%
SPCX
$149.59
▲+1.83%
AMD
$558.99
▲+5.22%
AAPL
$347.21
▲+0.96%
SNDK
$1,302.29
▲+3.72%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Artivion, Inc. Common Stock
(NY:
AORT
)
23.00
+0.02 (+0.09%)
Delayed Quote
Updated: 3:30 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Artivion, Inc. Common Stock
< Previous
1
2
3
4
5
6
Next >
Medical devices & supplies - cardiology, neurology, vascular stocks Q2 teardown: Artivion (NYSE:AORT) vs the rest
October 21, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Artivion (NYSE:AORT) and its ...
Via
StockStory
1 Small-Cap Stock with Exciting Potential and 2 We Turn Down
October 08, 2026
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Via
StockStory
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Headwinds
October 05, 2026
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu...
Via
StockStory
Topics
Economy
2 Growth Stocks with All-Star Potential and 1 We Find Risky
September 25, 2026
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...
Via
StockStory
Artivion Inc (NYSE:AORT) Catches the GARP Eye With Affordable Growth Screen
↗
May 14, 2026
Via
Chartmill
3 Healthcare Stocks We’re Skeptical Of
September 23, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
Via
StockStory
3 Profitable Stocks We Approach with Caution
September 11, 2026
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Via
StockStory
3 Reasons to Avoid AORT and 1 Stock to Buy Instead
September 08, 2026
What a brutal six months it’s been for Artivion. The stock has dropped 29.1% and now trades at $25.57, rattling many shareholders. This may have investors wo...
Via
StockStory
Topics
Supply Chain
3 Russell 2000 Stocks Walking a Fine Line
September 04, 2026
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...
Via
StockStory
Topics
Energy
1 High-Flying Stock to Own for Decades and 2 Facing Challenges
August 25, 2026
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
Via
StockStory
Why Artivion (AORT) Stock Is Trading Up Today
August 19, 2026
What Happened? Shares of medical device company Artivion (NYSE:AORT) jumped 2.5% in the afternoon session after Canaccord Genuity raised its price target on ...
Via
StockStory
Topics
Earnings
Artivion (AORT) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Revenue grew 9% as heart valve and stent graft products drove results.
Via
The Motley Fool
Topics
Earnings
5 Revealing Analyst Questions From Artivion’s Q2 Earnings Call
August 13, 2026
Artivion’s second quarter results were well received by the market, with performance driven by accelerating growth in its stent graft and On-X heart valve po...
Via
StockStory
Topics
Earnings
Artivion Q2 Earnings Call Highlights
↗
August 07, 2026
Artivion (NYSE:AORT) reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in...
Via
MarketBeat
Topics
Earnings
AORT Q2 Deep Dive: Product Momentum and Pipeline Expansion Support Positive Outlook
August 07, 2026
Medical device company Artivion (NYSE:AORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.3% year on year to $125.8 ...
Via
StockStory
Artivion (NYSE:AORT) Delivers Strong Q2 CY2026 Numbers
August 06, 2026
Medical device company Artivion (NYSE:AORT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.3% year on year to $125.8 mil...
Via
StockStory
Artivion (AORT) To Report Earnings Tomorrow: Here Is What To Expect
August 04, 2026
Medical device company Artivion (NYSE:AORT) will be reporting earnings this Thursday after the bell. Here’s what to expect. Artivion met analysts’ revenue ex...
Via
StockStory
3 Healthcare Stocks with Questionable Fundamentals
August 03, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...
Via
StockStory
3 Small-Cap Stocks We Keep Off Our Radar
July 30, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Via
StockStory
3 Reasons to Sell AORT and 1 Stock to Buy Instead
July 13, 2026
Artivion’s stock price has taken a beating over the past six months, shedding 43.8% of its value and falling to $24.10 per share. This was partly due to its ...
Via
StockStory
Topics
Supply Chain
3 Stocks Under $50 with Warning Signs
July 10, 2026
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...
Via
StockStory
2 Growth Stocks Set to Flourishand 1 We Ignore
July 02, 2026
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...
Via
StockStory
3 Profitable Stocks We Keep Off Our Radar
June 26, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
Topics
Electric Vehicles
World Trade
1 of Wall Street’s Favorite Stocks with Solid Fundamentals and 2 We Question
June 12, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via
StockStory
Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
June 08, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Artivion (NYSE:AORT) and its ...
Via
StockStory
3 High-Flying Stocks Walking a Fine Line
June 08, 2026
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...
Via
StockStory
3 Healthcare Stocks We Keep Off Our Radar
May 28, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl...
Via
StockStory
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
May 18, 2026
From
Endospan
Via
Business Wire
Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top Holding
↗
May 17, 2026
Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices.
Via
The Motley Fool
Topics
Bonds
ETFs
5 Insightful Analyst Questions From Artivion’s Q1 Earnings Call
May 14, 2026
Artivion’s first quarter results for 2026 were met with a significant negative market reaction, with investors responding to shortfalls in adjusted profitabi...
Via
StockStory
Topics
Earnings
< Previous
1
2
3
4
5
6
Next >
